Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA

RNAi technology is taking strong position among the key therapeutic modalities, with dozens of siRNA-based programs entering and successfully progressing through clinical stages of drug development. To further explore potentials of RNAi technology as therapeutics, we engineered and tested VEGFR2 siR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Liu, Xiaoxia, Wang, Wei, Samarsky, Dmitry, Liu, Li, Xu, Qian, Zhang, Wenqing, Zhu, Guangzu, Wu, Ping, Zuo, Xialin, Deng, Houliang, Zhang, Jingjing, Wu, Zhuomin, Chen, Xiaohui, Zhao, Lingfeng, Qiu, Zhiyong, Zhang, Zhongyi, Zeng, Qiyi, Yang, Wei, Zhang, Biliang, Ji, Aimin
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
RNA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4191406/
https://ncbi.nlm.nih.gov/pubmed/25223783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nar/gku831
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados